Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0.79% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 4.65% | < 30% | Pass |
| Interest-bearing investments / market cap | 0% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0.79% of any dividend from JUBLPHARMA should be given to charity. Calculate your amount →
The 3-month return is strongly positive but 1- and 6-month returns are negative, and the 50-day average is below the 200-day, pointing to a recovery within a broader sideways-to-weak context. The stock remains around 21% below its 52-week high, so the prior drawdown is not fully retraced.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.